Research Article

Sonodynamic Excitation of Rose Bengal for Eradication of Gram-Positive and Gram-Negative Bacteria

Faina Nakonechny,1,2 Michael Nisnevitch,1 Yeshayahu Nitzan,2 and Marina Nisnevitch1

1 Department of Chemical Engineering, Biotechnology and Materials, Ariel University Center of Samaria, 40700 Ariel, Israel
2 The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, 52900 Ramat-Gan, Israel

Correspondence should be addressed to Marina Nisnevitch; marinan@ariel.ac.il

Received 24 July 2012; Revised 26 August 2012; Accepted 24 September 2012

Academic Editor: Tim Maisch

Copyright © 2013 Faina Nakonechny et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Photodynamic antimicrobial chemotherapy based on photosensitizers activated by illumination is limited by poor penetration of visible light through skin and tissues. In order to overcome this problem, Rose Bengal was excited in the dark by 28 kHz ultrasound and was applied for inactivation of bacteria. It is demonstrated, for the first time, that the sonodynamic technique is effective for eradication of Gram-positive Staphylococcus aureus and Gram-negative Escherichia coli. The resultant sonodynamic effect was calculated as a 3–4 log10 reduction in bacteria concentration, depending on the cell and the Rose Bengal concentration and the treatment time. Sonodynamic treatment may become a novel and effective form of antimicrobial therapy and can be used for low-temperature sterilization of medical instruments and surgical accessories.

1. Introduction

The field of photodynamic antimicrobial chemotherapy (PACT) is currently under intense investigation and is showing promising prospects as an alternative to antibiotic treatment in view of increasing widespread bacterial resistance to antibiotics [1, 2]. A classical scheme of PACT includes excitation of low toxic components—photosensitizers (PS) by visible light, when light-activated PS molecules transfer energy to molecular oxygen, which results in the production of reactive oxygen species that in turn cause irreversible damage to cellular components [1, 3–7]. The list of PS includes a wide spectrum of compounds, such as porphyrins, phenothiaziniums, phthalocyanines, hypocrellin derivatives, squaraine derivatives (squaraine dyes, squaric acid derivatives), boron dipyrromethene derivatives, and chlorine derivatives [4, 6, 8]. PACT has been extensively studied as a strategy against both Gram-positive and Gram-negative bacteria [9, 10], including antibiotic-resistant species [11] and appears to occupy a niche for control of oral [12] and other localized infections [11]. It should be noted that no development of bacterial resistance to PS has been reported to date from the numerous studies on the effect of PACT against different microorganisms [13, 14].

The major disadvantage of PACT is the limited tissue penetration of external light. Despite advances in the development of light source devices for phototherapy [15, 16] and the clinical use of PACT in dermatology [5, 17], treatment of internal body tissues remains limited to invasive procedures. Only a few attempts to develop alternative means of PS activation have been reported to date. We [18–20] and others [21] developed an approach in which the external light source was replaced by chemiluminescent light emitted during the course of a chemical reaction. We used the chemiluminescent oxidation of luminol, in which the release of light energy was achieved without electrical or thermal input in the course of in situ conversion of molecular oxygen to superoxide ions. This technology, called chemiluminescent photodynamic antimicrobial therapy (CPAT), was shown to be effective against Gram-negative E. coli and Gram-positive S. aureus (both methicillin-sensitive and methicillin-resistant strains) [19, 20]. Our data showed that CPAT was almost as effective as PACT. CPAT can therefore compete with PACT.
may be exploited for treatment of infectious bacterial and viral diseases and proposed a new concept of sonodynamic antimicrobial chemotherapy (SACT) as a promising novel antimicrobial strategy. However, this hypothesis has not been proven experimentally.

In the present work it is demonstrated, for the first time, that SACT can indeed be realized. We show that Gram-positive *S. aureus* and Gram-negative *E. coli* can be eradicated by RB activated with ultrasound in the dark.

### 2. Materials and Methods

#### 2.1. Bacterial Growth. Cultures of *Staphylococcus aureus* (ATCC 25923) and *Escherichia coli* (ATCC 10798) were grown on brain-heart agar (BHA, Acumedia, USA) for 24 h, then were transferred into brain-heart broth (BH, Acumedia, USA) and were grown at 37°C and at a 170 rpm speed of shaking up to concentration of $10^9$ CFU mL$^{-1}$, centrifuged for 5 min at 10,000 rpm and diluted by sterile 0.05 M PBS, pH 7.5, to concentrations of 106–109 CFU mL$^{-1}$.

#### 2.2. Solutions of PS. Stock aqueous solutions of RB and Methylene Blue (MB) (Sigma-Aldrich, USA) were prepared in 0.016 mM and 0.013 mM concentrations, respectively, in PBS and filtered by sterile filtration through 0.22 μm membranes (Pall Corporation, USA). Visible spectra of the PS were registered using UV-Visible Spectrophotometer Cary 50 Bio (Varian, Australia).

#### 2.3. Testing of SACT. PS solutions were added to 10 mL portions of diluted *S. aureus* or *E. coli* in flat-bottom 2.5 cm diameter vials (solution height in the vials was 2 cm) and incubated for 15 min in the dark. Vials were held in a plastic holder tight to the bottom of an ultrasonic bath WUG-AO2H (Wise Clean Company, Korea) at 10°C and sonicated for 1-2 h at an ultrasonic frequency of 28 kHz and an intensity of 0.84 W cm$^{-2}$ (Figure 1). Strict conditions were maintained in order to prevent any external illumination during the experiments. 100 μL bacteria samples were diluted in several decimal dilutions and were spread over BHA plates with a Drigalsky spreader. The plates were incubated...
at 37°C overnight and CFU (colony-forming units) were counted taking dilutions into account. In control experiments bacterial cultures were tested in the absence of PS without sonication, in the absence of PS under sonication and in the presence of PS without sonication.

2.4. Testing of PACT. PACT experiments were carried out by illumination of bacteria cultured as described above in liquid BH medium, mixed with solutions of MB in glass test-tubes, incubated for 15 min in the dark and illuminated for 30 min at room temperature under temperature control by an 18 W white luminescent lamp placed at a distance of 15 cm from the tubes. Light intensity was 10.6 klux and a fluence rate was 1.6 mW cm\(^{-2}\). Light intensity was measured by a LX-102 Light-meter (Lutron, Taiwan). Samples were not sonicated in the PACT experiments.

2.5. Statistical Methods. The results obtained from at least 3 independent experiments fulfilled with duplicates were statistically analyzed by Anova single factor or by Anova two-factor analyses. The difference between the results was considered significant if the \(P\) value was less than 0.05.

3. Results and Discussion

Two types of cells were chosen for primary evaluation of the suitability of SDT for eradication of bacteria—\(E.\ coli\) for representing Gram-negative bacteria and \(S.\ aureus\) as a member of the Gram-positive group. Two compounds, RB and MB, were selected as potential sonosensitzers. These compounds are well known for their photodynamic activity against the chosen bacteria [19, 35–39], and what is more, sonodynamic anticancer activity of RB has been reported in several works [26, 40]. The sonodynamic activity of MB has not been studied, to the best of our knowledge, but several authors believe that photosensitizers are generally good candidates for exhibiting sonodynamic properties [22, 28]. RB and MB have good solubility in water, and this fact enabled building an experimental scheme based on their free forms in aqueous solutions.

The experiments for testing sonodynamic antibacterial properties of RB and MB were held in the dark in an ultrasonic bath with cold water (Figure 1). Pieces of ice were periodically added to the bath in order to compensate for heating of the water during the sonication procedure. All operations were performed in the dark in order to exclude any possibility of photodynamic excitation of the examined compounds. The following control experiments were carried out in all series in the dark: incubation of bacteria without sonication in the absence of RB and MB, incubation of bacteria without sonication in the presence of RB or MB, and sonication of bacteria in the absence of RB and MB. Various concentrations of the bacterial cultures were added to buffered aqueous solutions of RB or MB in flat vials and placed on the bottom of the ultrasound bath for sonication (Figure 1). The control vials, which were not sonicated, were incubated under similar conditions outside the bath in the dark.

The results of the SACT experiments demonstrating a sonodynamic effect of RB on \(E.\ coli\) are presented in Table 1 and Figure 2, and on \(S.\ aureus\) in Table 2 and Figure 3. When treated for 1 h, both \(E.\ coli\) and \(S.\ aureus\) bacteria were inhibited by RB under each tested concentration, and an increase in RB concentration caused higher suppression. Sonication of the cultures in the absence of RB led to a moderate decrease in cell concentration: sonication of cultures at a high initial bacterial concentration of \(10^9\) CFU mL\(^{-1}\) resulted in a ca. 2 log\(_{10}\) decrease in the number of CFU (Table 1), whereas sonication at a low initial concentration \((10^6\) and \(10^7\) CFU mL\(^{-1}\)) had no effect on the vitality of the bacteria when compared to the untreated control cells (\(P\) value = 0.322). Sonication of \(S.\ aureus\) not treated by RB resulted in a ca. 1 log\(_{10}\) decrease in the bacterial concentration for all initial bacterial cell concentrations.

![Figure 2: SACT effect of RB on \(E.\ coli\). Cells at initial concentration of \(10^6\) CFU mL\(^{-1}\) were incubated with 0–15 μM RB in an ultrasonic bath for 1 h in the dark. Controls: not sonicated bacterial cultures with or without PS. After the treatment, bacterial samples were serially diluted in 10-fold dilutions and evenly spread over HBA plates with a Drigalsky spreader. Plates were incubated at 37°C overnight and CFU were counted.](image-url)

| \(\log_{10} C_0\) | 0 | 5 | 10 | 15 |
|-----------------|---|---|----|----|
| \(+^*\)         | - | + | +  | +  |
| 6               | 5.8| 6.1| 3.2| 5.6|
|                 | 2.0| 5.5| 1.3| 5.5|
| 7               | 7.0| 6.9| 5.6| 6.8|
|                 | 4.5| 6.3| 3.7| 6.3|
| 9               | 7.1| 9.0| 6.8| 9.0|
|                 | 6.0| 8.2| 5.0| 8.1|

Plus (+) designates SACT treated samples and minus (−) designates controls. Treatment time was 1 h. \(C_0\): initial cell concentration, CFU mL\(^{-1}\).
Table 2: SACT effect of RB on S. aureus cells at various initial concentrations.

| log₁₀C₀ | + | – | + | – | + | – | + | – | – |
|---------|---|---|---|---|---|---|---|---|---|
| 6       | 5.0| 5.7| 1.4| 5.3| 0.8| 4.2| 0.01| 3.6| 7.9 |
| 7       | 6.0| 6.9| 3.7| 5.8| 2.9| 5.6| 1.7 | 5.6 |
| 9       | 7.9| 8.9| 6.6| 8.5| 6.3| 7.8| 5.4 | 7.5 |

*Plus (+) designates SACT treated samples and minus (–) designates controls. Treatment time was 1 h. C₀: initial cell concentration, CFU mL⁻¹.*

Figure 3: SACT effect of RB on S. aureus. Cells at initial concentration of 10⁶ CFU mL⁻¹ were incubated with 0–5 µM RB in an ultrasonic bath for 1 h in the dark. Controls: nonsonicated bacterial cultures with or without PS. After the treatment, bacterial samples were serially diluted in 10-fold dilutions and evenly spread over BHA plates with a Drigalsky spreader. Plates were incubated at 37°C overnight and CFU were counted.

Incubation of both bacteria in the absence of RB without sonication did not change the concentration of viable cells in all cases (Tables 1 and 2). The dark effect of RB, registered in nonsonicated series, depended on the initial cell concentration: for E. coli the maximal dark effect was ca. a 1 log₁₀ decrease (P value = 0.023) in CFU obtained for 15 µM RB at initial concentration of 10⁶ CFU mL⁻¹ (Table 1). This effect was even smaller and actually, insignificant, in the case of initial concentrations of 10⁵ and 10⁷ CFU mL⁻¹ for all RB concentrations—a 0.1–0.6 log₁₀ decrease in the E. coli vitality compared to the untreated control cells (P values = 0.40–0.72). For S. aureus the maximal dark effect was higher than that for E. coli—at 5 µM RB for all initial concentrations the vitality of S. aureus cells decreased by 1.5–2.5 log₁₀ in comparison with untreated cells (P values = 0.0238) (Table 2). Actually, in no case did application of either ultrasound or RB separately result in high suppression of the tested bacteria. Simultaneous use of RB and ultrasound in the dark showed quite different results. Inhibition of the treated by 15 µM RB E. coli cells was expressed by a 4–4.7 log₁₀ decrease in CFU compared to the untreated samples (P value = 0.041), (Table 1), and the highest eradication rate was achieved for an initial bacterial concentration of 10⁶ CFU mL⁻¹ treated by 15 µM RB, where the remaining E. coli concentration dropped to only 20 CFU mL⁻¹ (Figure 2). S. aureus was even more sensitive to the sonodynamic treatment. The bacteria were suppressed by 3.5–6 log₁₀ compared to the untreated samples (P values = 0.0078–0.018) at all initial cell concentrations (Table 2), and treatment by 5 µM RB at an initial concentration of 10⁶ CFU mL⁻¹ led to the most profound eradication of S. aureus (Figure 3). Taking into consideration separate dark and ultrasonic effects, we can conclude that the net contribution of sonodynamic treatment in the dark was ca. a 3 log₁₀ decrease in CFU. In the cases of both bacteria, application of SACT led to the antibacterial cytotoxic effect.

Prolonging the sonication caused a total bacterial suppression even at higher initial cell concentrations. S. aureus at an initial concentration of 10⁶ CFU mL⁻¹ and sonicated for 2 h in the presence of 5 µM RB was deeply eradicated, whereas after a 1 h treatment the number of viable cells was 50 CFU mL⁻¹ (Figure 4).

Another PS previously shown to be very effective in photodynamic eradication of the bacteria examined in the present study [19, 20, 38, 39], namely MB, was tested under SACT conditions. S. aureus was studied at two initial concentrations of 10⁹ and 10⁸ CFU mL⁻¹. MB demonstrated a low dark effect in the absence of sonication and the concentration of S. aureus cells decreased by 1.2 log₁₀ at both initial cell concentrations. At initial bacterial concentration of 10⁶ CFU mL⁻¹ sonication in the absence of MB caused a 1.4 log₁₀ decrease in CFU, and in the presence of MB—a 1.7 log₁₀ reduction in the S. aureus concentration. The difference between these data was insignificant (P value = 0.39). In the case of initial cell concentration of 10⁶ CFU mL⁻¹ the difference was even less (Figure 5) and reached a 0.26 log₁₀ decrease in the absence of MB and a 0.3 log₁₀ decrease in the presence of MB (P value = 0.76). The results of the control experiments were very similar to those obtained in the RB study (Table 2), but in contradistinction to RB, MB was not found to exhibit any sonodynamic activity. Additional control experiments on the photodynamic activity of MB were performed in order to rule out possible occasional inactivity of the batch of MB used for S. aureus eradication. S. aureus illuminated by white light in the absence of MB was practically unaffected, whereas the bacteria were totally eradicated in the presence of MB (Figure 5).

Inefficacy of MB in the SACT experiment was quite surprising for us and it can be assumed that not all the PS can be excited by ultrasound. Probably, sensitivity of PS to sonication depends on the structure of the molecules, especially...
The obtained data provide indirect evidence that the mechanism of SACT is probably based on sonoluminescent excitation of PS. Sonoluminescent light has a broadband spectrum from 200 to 700 nm, but the maximum emission intensity of sonoluminescence in water lies between 250 and 600 nm [41]. This emission range correlates well with the absorbance spectrum of RB, but has almost no overlap with the spectrum of MB (Figure 6), thus affording an explanation for the high rate of RB activation by SACT and negligible sonoexcitation of MB.

Figures 2 and 3 demonstrate that the Gram-positive *S. aureus* responded to the sonodynamic treatment with RB much better than the Gram-negative *E. coli*, where the eradication rates were higher at lower applied RB concentrations for all initial cell concentrations. The same tendency was observed for PACT [38, 39] and was explained by differences in the complex molecular and physico-chemical structure of the cell membranes of the two bacterial groups [42]. The initial cell concentration played a crucial role in the process of bacterial eradication by SACT. For all examined conditions.
concentrations of RB the SACT effect was more pronounced for low initial bacterial concentrations and less exhibited for concentrated bacterial suspensions. The highest eradication of both bacteria was achieved when cells at low concentration were treated by PS at high concentration (Tables 1 and 2). Probably SACT effect depends on PS dose to bacterial concentration ratio. Analogous phenomenon of different effect of PS on bacterial cells at various concentrations was registered earlier in PACT experiments [39] and it was shown that at low concentrations bacteria showed stronger susceptibility for PACT treatment.

As in the case of cancer treatment, combating bacterial infections in vivo can be more effective and with fewer side effects when targeted to the site of infection. In addition to known methods of targeting drugs to cells, including antibody, protein or peptide, liposomal, and magnetic targeting [43–50], use of ultrasound affords a direct and exact focusing on the treated site. Nonactivated PS does not harm healthy tissues. Thus, excitation of the PS only after it has reached the treatment site will prevent systemic toxic effects during delivery of the drug to the treatment site. Such targeted treatment was carried out on cancer cells in mice by Yumita et al. [29] and Umemura et al. [51] and resulted in cessation of tumor growth [51] or even in destruction of tumor tissue [29]. The same targeting scheme can undoubtedly be applied for antibacterial treatment.

In addition to future potential therapeutic applications of SACT, a method for cold sterilization of medical instruments and surgical accessories could be proposed. A simple addition of sonosensitizers, for example of RB, to the aqueous phase in the ultrasonic bath will significantly improve and increase the effectiveness of the sterilization process.

4. Conclusions

The present work shows for the first time, that sonodynamic activation of RB causes eradication of E. coli and S. aureus in the dark. The described novel SACT technique has good prospects for becoming an effective targeted tool for combating internal infections and for cold sterilization of medical instruments.

Acknowledgments

This research was supported in part by the Research Authority of the Ariel University Center of Samaria, Israel, by the Cherna Moskowitz Foundation, Calif, USA, and by the Rappaport Foundation for Medical Microbiology, Bar Ilan University, Israel (to Y. Nitzan).

References

[1] T. Maisch, “Anti-microbial photodynamic therapy: useful in the future?” Lasers in Medical Science, vol. 22, no. 2, pp. 83–91, 2007.
[2] T. Maisch, “A new strategy to destroy antibiotic resistant microorganisms: antimicrobial photodynamic treatment,” Mini-Reviews in Medicinal Chemistry, vol. 9, no. 8, pp. 974–983, 2009.
[3] I. E. Kocheva, C. R. Lamb, M. C. Lynch, and A. C. Tedesco, “Comparison of photosensitized plasma membrane damage caused by singlet oxygen and free radicals,” Biochimica et Biophysica Acta, vol. 1280, no. 2, pp. 223–230, 1996.
[4] I. J. MacDonald and T. J. Dougherty, “Basic principles of photodynamic therapy,” Journal of Porphyrins and Phthalocyanines, vol. 5, no. 2, pp. 105–129, 2001.
[5] T. Maisch, R. M. Szeimies, G. Jori, and C. Abels, “Antibacterial photodynamic therapy in dermatology,” Photochemical and Photobiological Sciences, vol. 3, no. 10, pp. 907–917, 2004.
[6] S. Yano, S. Hirohara, M. Obata et al., “Current states and future views in photodynamic therapy,” Journal of Photochemistry and Photobiology C, vol. 12, no. 1, pp. 46–67, 2011.
[7] K. Plaetzer, T. Kiesslich, T. Verwanger, and B. Kramer, “The modes of cell death induced by PDT: an overview,” Medical Laser Application, vol. 18, no. 1, pp. 7–19, 2003.
[8] J. Berlanda, T. Kiesslich, V. Engelhardt, B. Kramer, and K. Plaetzer, “Comparative in vitro study on the characteristics of different photosensitizers employed in PDT,” Journal of Photochemistry and Photobiology B, vol. 100, no. 3, pp. 173–180, 2010.
[9] M. Wainwright, “Photodynamic antimicrobial chemotherapy (PACT),” Journal of Antimicrobial Chemotherapy, vol. 42, no. 1, pp. 13–28, 1998.
[10] C. M. Cassidy, M. M. Tunney, P. A. McCarron, and R. F. Donnelly, “Drug delivery strategies for photodynamic antimicrobial chemotherapy: from benchtop to clinical practice,” Journal of Photochemistry and Photobiology B, vol. 95, no. 2, pp. 71–80, 2009.
[11] K. O’Riordan, O. E. Akilov, and T. Hasan, “The potential for photodynamic therapy in the treatment of localized infections,” Photodiagnosis and Photodynamic Therapy, vol. 2, no. 4, pp. 247–262, 2005.
[12] P. Meisel and T. Kocher, “Photodynamic therapy for periodontal diseases: state of the art,” Journal of Photochemistry and Photobiology B, vol. 79, no. 2, pp. 159–170, 2005.
[13] T. Dai, Y. Y. Huang, and M. R. Hamblin, “Photodynamic therapy for localized infections—state of the art,” Photodiagnosis and Photodynamic Therapy, vol. 6, no. 3–4, pp. 170–188, 2009.
[14] A. Tavares, C. M. B. Carvalho, M. A. Faustino et al., “Antimicrobial photodynamic therapy: study of bacterial recovery viability and potential development of resistance after treatment,” Marine Drugs, vol. 8, no. 1, pp. 91–105, 2010.
[15] L. Brancaleon and H. Moseley, “Laser and non-laser light sources for photodynamic therapy,” Lasers in Medical Science, vol. 17, no. 3, pp. 173–186, 2002.
[16] A. Pieslinger, K. Plaetzer, C. B. Oberdanner et al., “Characterization of a simple and homogeneous irradiation device based on light-emitting diodes: a possible low-cost supplement to conventional light sources for photodynamic treatment,” Medical Laser Application, vol. 21, no. 4, pp. 277–283, 2006.
[17] O. Ceburkov and H. Gollnick, “Photodynamic therapy in dermatology,” European Journal of Dermatology, vol. 10, no. 7, pp. 568–576, 2000.
[18] R. Laptev, M. Nisnevitch, G. Siboni, Z. Malik, and M. A. Firer, “Intracellular chemiluminescence activates targeted photodynamic destruction of leukaemic cells,” British Journal of Cancer, vol. 95, no. 2, pp. 189–196, 2006.
[19] F. Nakonechny, M. A. Firer, Y. Nitzan, and M. Nisnevitch, “Intracellular antimicrobial photodynamic therapy: a novel technique for efficient eradication of pathogenic bacteria,”
A. Juarranz, J. Espada, J. C. Stockert et al., “Photodamage,” 2010.

[20] F. Nakonechny, M. Nisnevitch, Y. Nitzan, and M. A. Firer, “New techniques in antimicrobial photodynamic therapy: scope of application and overcoming drug resistance in nosocomial infections,” in *Science Against Microbial Pathogens: Communicating Current Research and Technological Advances*, Microbiology Book Series, no. 3, Formatex Research Center, Spain, 2011.

[21] S. Carpenter, M. J. Fehr, G. A. Kraus, and J. W. Petrich, “Chemiluminescent activation of the antiviral activity of hypericin: a molecular flashlight,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 91, no. 25, pp. 12273–12277, 1994.

[22] I. Rosenthal, J. Z. Sostaric, and P. Riesz, “Sonodynamic therapy—a review of the synergistic effects of drugs and ultrasound,” *Ultrasonics Sonochemistry*, vol. 11, no. 6, pp. 349–363, 2004.

[23] P. Wang, L. Xiao, X. Wang, X. Li, and Q. Liu, “Sonodynamic effects of protoporphyrin IX disodium salt on Ehrlich ascitic tumor cells,” *Ultrasonics*, vol. 50, no. 6, pp. 634–638, 2010.

[24] X. Zhao, Q. Liu, W. Tang et al., “Damage effects of protoporphyrin IX—sonodynamic therapy on the cytoskeletal F-actin of Ehrlich ascites carcinoma cells,” *Ultrasonics Sonochemistry*, vol. 16, no. 1, pp. 50–56, 2009.

[25] K. Tachibana, L. B. Feril, and Y. Ikeda-Dantsuji, “Sonodynamic therapy,” *Lasers in Surgery and Medicine*, vol. 29, no. 2, pp. 165–173, 2001.

[26] M. Nisnevitch, F. Nakonechny, and Y. Nitzan, “Photodynamic antimicrobial chemotherapy by liposome-encapsulated water-soluble photosensitizers,” *Russian Journal of Bioorganic Chemistry*, vol. 36, no. 3, pp. 363–369, 2010.

[27] F. Nakonechny, Y. Nitzan, and M. Nisnevitch, “Olive oil based delivery of photosensitizers for bacterial eradication,” in *Olive Oil*, InTech, Rijeka, Croatia, 2012.

[28] W. Hiraoka, H. Honda, L. B. Feril, N. Kudo, and T. Kondo, “Comparison between sonodynamic effect and photodynamic effect with photosensitizers on free radical formation and cell killing,” *Ultrasonics Sonochemistry*, vol. 13, no. 6, pp. 535–542, 2006.

[29] S. C. Carpenter, M. J. Fehr, G. A. Kraus, and J. W. Petrich, “Chemiluminescent activation of the antiviral activity of hypericin: a molecular flashlight,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 91, no. 25, pp. 12273–12277, 1994.

[30] P. D. Sharma, “Microbiology,” Rastogy Publications, New Delhi, India, 2007.

[31] M. N. Jones, M. Kaszuba, K. J. Hill, Y. H. Song, and J. E. Creeth, “The use of phospholipid liposomes for targeting to oral and skin-associated bacteria,” *Journal of Drug Targeting*, vol. 2, no. 5, pp. 381–389, 1994.

[32] M. N. Jones, M. Kaszuba, M. D. Reboiras et al., “The targeting of phospholipid liposomes to bacteria,” *Biochimica et Biophysica Acta*, vol. 1396, no. 2, pp. 278–286, 1998.

[33] A. M. Robinson, J. E. Creeth, and M. N. Jones, “The specificity and affinity of immunoliposome targeting to oral bacteria,” *Biochimica et Biophysica Acta*, vol. 1369, no. 2, pp. 57–64, 1994.

[34] A. S. Manjappa, K. R. Chaudhari, M. P. Venkataraju et al., “Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor,” *Journal of Controlled Release*, vol. 150, no. 1, pp. 2–22, 2011.

[35] H. A. Franks, Q. Wang, and P. M. Patel, “New anticaner immunotherapies,” *Anticancer Research*, vol. 32, no. 7, pp. 2439–2453, 2012.

[36] S. Cohen, R. Cahan, E. Ben-Dov, M. Nisnevitch, A. Zaritsky, and M. A. Firer, “Specific targeting to murine myeloma cells of Cyt1Aa toxin from *Bacillus thuringiensis* subspecies *israelensis*,” *Journal of Biological Chemistry*, vol. 282, no. 39, pp. 28301–28308, 2007.

[37] K. Umemura, N. Yumita, R. Nishigaki, and S. I. Umemura, “Sonodynamically induced antitumor effect of phophorbide a,” *Cancer Letters*, vol. 102, no. 1-2, pp. 151–157, 1996.